Bacterial strain with effects of resisting allergy and improving immunity and application of bacterial strain

Abstract

The invention discloses a strain with anti-allergy and immunity improving effects and application of the strain. The strain is Lactobacillus acidophilus L59, is preserved in Guangdong Microbial Culture Collection Center, and has the preservation number of GDMCC NO.64842. The invention also discloses a preparation method of the strain. The preservation time is July 8, 2024; the strain with the anti-allergy and immunity-improving effects is obtained through screening, the strain has the anti-allergy and immunity-improving effects, IgE and histamine in serum of allergic mice can be reduced, then allergic symptoms can be relieved, and the strain takes effect quickly and is remarkable in effect.

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to a strain with anti-allergy and immunity-enhancing effects and application thereof. Background Art

[0002] Under normal circumstances, when foreign substances enter the human body, they mostly face two fates. If they are recognized by the body as useful or harmless substances, they will coexist harmoniously with the human body and will eventually be absorbed, utilized or naturally excreted. If these substances are recognized as harmful substances, the body's immune system will immediately respond to expel or eliminate them. This is the protective role played by the immune response. Immune response is one of the important functions of the human defense system, but if this response exceeds the normal range, that is, when the immune system attacks harmless substances, this situation is called an allergic reaction. Allergic reaction is a disease, because unprovoked attacks can also damage normal body tissues, and even the immune system sometimes attacks and destroys the body's own tissues, which is very detrimental to human health. In short, allergic reaction is not a psychological abnormality, but a "perverted" function of the body's immune system. Clinically, according to the classification principle proposed by Coombs and Gell in 1963, allergic reactions are divided into type I (immediate type), type II (cytotoxic type); type III (immune complex type), and type IV (delayed type). Allergy is the main representative of type I hypersensitivity reaction, which is clinically divided into allergic reaction and allergic disease. The former is a systemic syndrome in which the body reacts abnormally to allergens. The latter is that allergy affects a certain organ and tissue, leading to the occurrence of a certain disease. Common allergic diseases include allergic asthma, allergic rhinitis, hay fever, certain dermatitis, etc.

[0003] Current studies have shown that probiotics can relieve allergic reactions, but different probiotics have different anti-allergic properties. Therefore, it is particularly important to provide a new probiotic with excellent anti-allergic properties. Summary of the invention

[0004] The purpose of the present invention is to provide a strain with anti-allergic and immunity-enhancing effects and its application. The strain of the present invention has anti-allergic and immunity-enhancing effects and can relieve allergic symptoms.

[0005] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0006] The first aspect of the present invention provides a strain with anti-allergic and immunity-enhancing effects, wherein the strain is Lactobacillus acidophilus L59, which is deposited in Guangdong Provincial Microbiological Culture Collection Center with a deposit number of GDMCC NO.64842; the deposit time is July 8, 2024.

[0007] The second aspect of the present invention provides a microbial agent containing the strain having anti-allergic and immunity-enhancing effects.

[0008] Preferably, the microbial agent is obtained by inoculating the strain with anti-allergic and immunity-enhancing effects into a culture medium for cultivation.

[0009] The third aspect of the present invention provides a use of the strain having anti-allergic and immunity-enhancing effects or the microbial agent in the preparation of an anti-allergic product.

[0010] Preferably, the product is a medicine, a food or a health product.

[0011] The fourth aspect of the present invention provides an anti-allergic product, comprising the strain or the microbial agent having anti-allergic and immunity-enhancing effects.

[0012] Preferably, the viable count of the strain with anti-allergic and immunity-enhancing effects is not less than 1×10 8 cfu / g, or the number of cells in the microbial agent is not less than 1×10 8 cells / g.

[0013] Compared with the prior art, the beneficial effects of the present invention include at least:

[0014] The present invention screens out a strain with anti-allergic and immunity-enhancing effects. The strain has anti-allergic and immunity-enhancing effects and can reduce IgE and histamine in the serum of allergic mice, thereby alleviating allergic symptoms, with rapid and significant effects; in addition, the body's immunity can also be improved. DETAILED DESCRIPTION

[0015] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the embodiments. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0016] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should have the common meanings understood by those skilled in the art to which the present invention belongs.

[0017] The embodiment of the present invention provides a strain with anti-allergic and immunity-enhancing effects, wherein the strain is Lactobacillus acidophilus L59, which is preserved in the Guangdong Provincial Microbiological Culture Collection Center with a preservation number of GDMCC NO.64842; the preservation time is July 8, 2024.

[0018] The present invention screens out a strain with anti-allergic and immunity-enhancing effects. The strain has anti-allergic and immunity-enhancing effects and can reduce IgE in the serum of allergic mice, thereby alleviating allergic symptoms, with rapid and significant effects. In addition, the strain can also improve the body's immunity.

[0019] Another embodiment of the present invention provides a microbial agent containing the strain having anti-allergic and immunity-enhancing effects.

[0020] In one embodiment, the microbial agent is obtained by inoculating the strain having anti-allergic and immunity-enhancing effects into a culture medium for cultivation.

[0021] Another embodiment of the present invention provides a use of the strain having anti-allergic and immunity-enhancing effects or the microbial agent in the preparation of anti-allergic products.

[0022] In one embodiment, the product is a medicine, a food or a health product.

[0023] Still another embodiment of the present invention provides an anti-allergic product, wherein the anti-allergic product comprises the strain or the microbial agent having anti-allergic and immunity-enhancing effects.

[0024] In one embodiment, the viable count of the strain having anti-allergic and immunity-enhancing effects is not less than 1×10 8 cfu / g. Specifically, in one embodiment, the viable count of the strain with anti-allergic and immunity-enhancing effects is 2×10 8 cfu / g. In other embodiments, the viable count of the strain with anti-allergic and immunity-enhancing effects is 5×10 9 cfu / g; in other embodiments, the number of cells in the microbial agent is not less than 1×10 8 cells / g.

[0025] In the present invention, by limiting the content of strains having anti-allergic and immunity-enhancing effects, it can be better ensured that the prepared product has a more excellent anti-allergic effect.

[0026] The technical solution of the present invention is further described in detail below through specific embodiments.

[0027] Example 1

[0028] This example is the screening of Lactobacillus acidophilus L59;

[0029] Several samples of fresh feces from 3-year-old children in Zhongxiang City, Hubei Province were collected using a disposable sterile stool sampler. After gradient dilution, they were applied to LBS culture medium supplemented with 1% nystatin and enriched in an anaerobic incubator for 48 hours. After cultivation, colonies were picked with an inoculation loop and streaked for purification based on the color, size, edge shape, etc. of the colonies. After identification, a strain of Lactobacillus acidophilus L59 was obtained.

[0030] The morphological identification characteristics of Lactobacillus acidophilus L59 are as follows: slightly curved under a microscope, the colonies are milky white, and the edges are curled.

[0031] Example 2

[0032] This example is a study on the functional effects of Lactobacillus acidophilus L59:

[0033] 1. Construction of allergy model:

[0034] BALB / c mice were selected for breeding and randomly divided into 3 groups, of which group 1 was blank control, group 2 was model control, and group 3 was experimental group;

[0035] The mice in group 2 and group 3 were intraperitoneally injected with an equal volume of OVA (0.2 mg / ml) and Freund's adjuvant emulsion. The injection volume was 2 ml, and the injection was once every 5 days. After 3 injections, the mice were then gavaged with 2 ml of 20 mg / ml OVA solution on the 20th, 23rd and 28th days respectively.

[0036] During the sensitization period, mice in group 3 were gavaged with Lactobacillus acidophilus L59 in saline solution (1×10 8 cfu / ml) 2ml, group 2 was injected with normal saline;

[0037] On the 30th day, blood was collected to test the IgE and histamine levels in the serum and the average values ​​were calculated;

[0038] The test results are shown in Table 1;

[0039] Table 1

[0040] Group IgE (ug / mL) Histamine (ng / mL) Group 1 0.13 1.41 Group 2 6.17 4.78 Group 3 2.08 1.73

[0041] From Table 1, we can see that:

[0042] The Lactobacillus acidophilus L59 of the present application can significantly reduce the IgE and histamine levels in the serum of sensitized mice, indicating that the Lactobacillus acidophilus L59 of the present invention can relieve allergic symptoms and has anti-allergic efficacy.

[0043] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. A strain with anti-allergic and immunity-enhancing effects, characterized in that: The strain is Lactobacillus acidophilus L59, which is preserved in Guangdong Provincial Microbiological Culture Collection Center with the preservation number GDMCCNO.64842; the preservation time is July 8, 2024.

2. A microbial agent containing the strain having anti-allergic and immunity-enhancing effects as claimed in claim 1.

3. The microbial agent according to claim 2, characterized in that: The microbial agent is obtained by inoculating the strain with anti-allergic and immunity-enhancing effects into a culture medium for cultivation.

4. Use of the anti-allergic and immunity-enhancing bacterial strain of claim 1 or the microbial agent of any one of claims 2 to 3 in the preparation of anti-allergic products.

5. The use according to claim 4, characterized in that: The product is a medicine, food or health product.

6. An anti-allergic product, characterized in that: It includes the strain with anti-allergic and immunity-enhancing effects as described in claim 1 or the microbial agent as described in any one of claims 2 to 3.

7. The product according to claim 5, characterized in that The viable bacterial count of the strain with anti-allergic and immunity-enhancing effects is not less than 1×10 8 cfu / g, or the number of cells in the microbial agent is not less than 1×10 8 cells / g.